Floatz logo

CEFTOLOZANE

Burkholderia Cepacia Infection

Sunshine Coast Hospital and Health ServiceSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Burkholderia Cepacia Infection cohort.

Asset / SponsorPhaseRating
Tazobactam
Sunshine Coast Hospital and Health Service
Phase 4BB
Aztreonam Lysine
Gilead Sciences
Phase 3BB
POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)
Synspira, Inc.
Phase 1CC
Alginate Oligosaccharide
AlgiPharma AS
Phase 2NR

Same molecule, other indications

CEFTOLOZANE is also rated in:

Pseudomonas infectionDormant
BB
Indicative ·
69 / 100
View asset →
bronchiectasisDormant
BB
Indicative ·
65 / 100
View asset →
Pseudomonas aeruginosa infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →